PlainRecalls
FDA Drug Moderate Class II Ongoing

Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg, (a) 90-count bottle (NDC 0378-6324-77), (b) 500-count bottles (NDC 0378-6324-05), Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.

Reported: December 19, 2018 Initiated: December 4, 2018 #D-0331-2019

Product Description

Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg, (a) 90-count bottle (NDC 0378-6324-77), (b) 500-count bottles (NDC 0378-6324-05), Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.

Reason for Recall

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Details

Units Affected
19,352 HDPE bottles
Distribution
Product was distributed throughout the United States to several major distributors, including Puerto Rico.
Location
Sinnar, Nashik District, N/A

Frequently Asked Questions

What product was recalled?
Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg, (a) 90-count bottle (NDC 0378-6324-77), (b) 500-count bottles (NDC 0378-6324-05), Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.. Recalled by Mylan Laboratories Limited, (Nashik FDF). Units affected: 19,352 HDPE bottles.
Why was this product recalled?
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Which agency issued this recall?
This recall was issued by the FDA Drug on December 19, 2018. Severity: Moderate. Recall number: D-0331-2019.